SecBot SecBot

HOWL drug pipeline

$0.9910
+1.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
3
1 bearish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketTopline Phase 3 results expected in 2028, NDA submission thereafter, potential FDA approval likely no earlier than 2029 if the trial succeeds.

neridronate neridronic acid Updated Nov 11

What to watch

Watch for the timing and outcome of the CRPS-RISE interim analysis, which could allow the trial to stop early for efficacy or futility. The merger with Ambros is still being finalized (S-4/A filed November 10, 2026), and current HOWL shareholders face massive dilution, owning roughly 7% of the combined entity. The $150 million PIPE is expected to fund the company through topline results in 2028 and into 2029, reducing near-term financing risk.

Bull case
  • CRPS-1 affects roughly 65,000 newly diagnosed U.S. patients annually with no currently FDA-approved treatment, representing a large unmet need and potential orphan-drug commercial opportunity.
  • Neridronate has FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, providing regulatory advantages including expedited review and potential market exclusivity.
  • The $150 million oversubscribed PIPE is expected to fully fund the company through Phase 3 topline results in 2028 and into the first half of 2029, reducing near-term dilution risk.
Bear case
  • Neridronate is still in Phase 3 with no topline data yet; Phase 3 trials in pain indications have a high historical failure rate.
  • Current HOWL shareholders will own only roughly 7% of the combined company post-merger, representing massive dilution for existing holders.
  • Analyst coverage is stale (last action December 2025) and the consensus is mixed: 3 hold, 1 sell, 2 strong sell ratings with a mean price target of $7 (though coverageStale flag is true).
▼ bearish
Impact
Phaseunknown — not confirmed this session (SecBot's FDA/ClinicalTrials.gov ingestion holds no WTX-124 records; external web s
Time to marketUnknown — no approval timeline exists in available sources; multi-year (if ever) from its current stage, and the program's future is clouded by the company's strategic review.

WTX-124 Updated Aug 3

What to watch

Watch the strategic-alternatives process (no defined timeline per the July 31, 2026 Q2 update), WTX-124's fate is likely a sale/partnership or wind-down rather than a clinical binary. Also watch the cash runway: ~$22.0M at June 30, 2026 against ~$13.8M in quarterly operating expenses, with the company guiding to funding into Q2 2027. Repeated Form 144 filings from backers MPM, RA Capital and UBS Oncology and a 10.3% rise in short positions (July 15 settlement) argue against expecting a near-term squeeze.

Bull case
  • WTX-124 is still an active pipeline asset, it is named among Werewolf's drug programs (WTX-124, WTX-330, WTX-1011, WTX-2022) in the Q2 2026 8-K, meaning it has not been discontinued or sold off like JZP898.
  • The platform concept is differentiated and the company is debt-free with ~$22.0M cash and guidance to fund operations into Q2 2027, giving some time for a strategic outcome.
  • Sell-side remains constructive on the name: July 2026 consensus shows 4 buy + 4 strong buy vs 2 hold (0 sell), and Wedbush's rated calls on HOWL score 100% accuracy (top tier) in SecBot's benchmark.
Bear case
  • No hard, dated catalyst for WTX-124 exists in the next ~12 months in any available source, no PDUFA, no scheduled readout, no trial records in SecBot's FDA/ClinicalTrials.gov data.
  • Cash crunch: $22.0M cash at June 30, 2026 (down from $46.5M at Q1 end) against ~$13.8M quarterly operating expenses; Q2's $0.08 EPS 'beat' was 100% a one-time asset sale, masking ongoing losses, and management says the strategic review has no defined timeline or guarantee.
  • Coordinated selling by pre-IPO backers: multiple Form 144s from MPM-affiliated funds, UBS Oncology Impact Fund, and 10% owner RA Capital, plus director Luke Evnin 10b5-1 sales, with no insider buys recorded.
● neutral
Impact
PhaseUnknown/unverified — no Phase 2/3 industry-sponsored records for WTX-330 exist in SecBot's ingested ClinicalTrials.gov d
Time to marketUnknown — clinical stage could not be verified this session (no web access, no SecBot FDA/trial records for WTX-330).

WTX-330 wtx-330 (development code; no INN/generic name verified this session) Updated Aug 3

What to watch

Before any position, verify WTX-330's actual clinical stage and next data-readout date from Werewolf's IR site and press releases, this session's tools could not retrieve them. Note the setup: a ~$0.36 micro-cap where the single-analyst $7 target implies massive upside but where zero SecBot-ingested Phase 2/3 trial records exist for this drug, so near-term moves are likely binary, event-driven, and unverifiable here.

Bull case
  • Latest analyst snapshot is net positive: 8 Buy/Strong-Buy ratings vs 2 Hold and 0 Sell for HOWL.
  • Price-target snapshot shows a $7 mean target vs a $0.3531 stored current price, the tool's impliedUpside field reads 1825.2% (single analyst in that snapshot; treat as thin).
  • Micro-cap quote (~$0.36) means even modest positive early clinical news on any lead candidate can produce outsized percentage moves.
Bear case
  • No WTX-330 clinical records exist in SecBot's ingested Phase 2/3 ClinicalTrials.gov or FDA datasets, and no external coverage could be retrieved, phase/status is unverifiable, and an early-stage program is likely years from commercialization with high failure risk.
  • Insider selling is ongoing: director (MPM-affiliated) 10b5-1-plan sales of ~$33k (2026-07-07), ~$11k (2026-07-06) and ~$47k (2026-06-29) gross per Form 4s, pre-planned, but adds supply overhang at a ~$0.36 quote.
  • Deep-micro-cap financing risk: funding early clinical trials typically requires dilution at these price levels, and the gap between the single-analyst $7 target and the ~$0.36 quote illustrates binary, event-driven volatility.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
WTX-330A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or LymphomaPhase 2Completed24Apr 23, 2026